MRSA Notes

Retapamulin belongs to a new class of antibiotics called pleuromutilins and is being developed for the topical treatment of uncomplicated skin and skin structure infections due to susceptible strains of Staphylococcus aureus or Streptococcus pyogenes.

“A growing cause of many community and hospital-acquired infections are gram-positive bacteria, such as streptococci and staphylococci, and their resistance to antibiotics is on the rise,” said Clarence Young, MD, Vice-President, Infectious Diseases Medicines Development Centre, GlaxoSmithKline. “These studies showed that retapamulin not only demonstrated promising in vitro activity against these specific types of bacteria, it also may have a low propensity to generate drug resistance.”

Read more: First In New Class Of Antibacterials Demonstrates Promising Activity Against Pathogens Commonly Found In Skin Infections

Share This